>

Cholangiocyte (large 2)

Q: Can I use the Cholangiocyte (large 2) icon in a BioRender figure or scientific illustration?

Yes — the Cholangiocyte (large 2) is fully integrated into BioRender's drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you're building from scratch or starting with a BioRender template.

Q: Can I export figures that include the Cholangiocyte (large 2) icon for publication or presentations?

Yes — figures containing the Cholangiocyte (large 2) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

Cholangiocyte (large 2) - Editable icon of a columnar, triangular large cholangiocyte with a nucleus

[{"image":"https://icons.cdn.biorender.com/w75xh75/5be1f29e6f3d0b12005a99e4/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5be1f29e6f3d0b12005a99e4/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/5be1f29e6f3d0b12005a99e2/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/5be1f29e6f3d0b12005a99e2/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382ad/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382ad/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382ae/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382ae/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382af/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382af/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382b0/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382b0/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382b1/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382b1/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382b2/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382b2/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382b3/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382b3/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382b4/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382b4/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382b5/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382b5/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382b6/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382b6/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382b7/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382b7/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382b8/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382b8/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382b9/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382b9/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382ba/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382ba/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382bb/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382bb/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382bc/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382bc/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382bd/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382bd/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382be/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382be/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382bf/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382bf/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382c0/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382c0/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382c1/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382c1/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382c2/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382c2/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382c3/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382c3/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382c4/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382c4/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382c5/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382c5/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382c6/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382c6/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382c7/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382c7/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382c8/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382c8/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382c9/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382c9/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382ca/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382ca/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382cb/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382cb/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382cc/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382cc/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382cd/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382cd/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382ce/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382ce/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382cf/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382cf/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382d0/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382d0/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382d1/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382d1/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382d2/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382d2/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382d3/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382d3/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382d4/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382d4/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382d5/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382d5/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382d6/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382d6/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382d7/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382d7/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382d8/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382d8/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382d9/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382d9/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382da/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382da/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382db/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382db/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382dc/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382dc/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382dd/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382dd/5be1f2746f3d0b12005a99d7.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/66da0e033ccf015b9bb382de/5be1f2746f3d0b12005a99d7.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/66da0e033ccf015b9bb382de/5be1f2746f3d0b12005a99d7.png"}]

Keywords

keyword text

bile,gallbladder,bile duct,biliary system,digestive system,cholangiocyte,large cholangiocyte

BioRender icons and templates meet journal, grant, and copyright standards. For AI-generated figures, policies vary. Learn More

More Icons like this one in

Related Categories

Back To Library Home

Join 1,500,000 other scientists on BioRender

Sign up for your free account and start creating scientific figures faster today

Sign Up Free

FAQs

What is BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Cholangiocyte (large 2) icon along with our library of more than 30,000 life science icons.

Can I use this icon in a BioRender figure or scientific illustration?

Yes, the Cholangiocyte (large 2) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Cholangiocyte (large 2) icon customizable in BioRender?

Most icons in BioRender, including the Cholangiocyte (large 2) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

How are scientists using the Cholangiocyte (large 2) icon in their work?

BioRender users often use the Cholangiocyte (large 2) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

Can I export figures that include the Cholangiocyte (large 2) icon for publication or presentations?

Yes, figures containing the Cholangiocyte (large 2) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

Is the Cholangiocyte (large 2) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Cholangiocyte (large 2) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

Make scientific figures in minutes

Cholangiocyte (large 2)

Join 1,500,000 other scientists on BioRender

FAQs

Looking for science content?